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Background and objectives: The relationship between mineral metabolism disorders, bone
fractures and vascular calciﬁcations in kidney transplant recipients has not been estab-
lished.
Method: We  performed a cross-sectional study in 727 stable recipients from 28 Spanish trans-
plant  clinics. Mineral metabolism parameters, the semi-quantiﬁcation of vertebral fractures
and abdominal aortic calciﬁcations were determined centrally.
Results: Vitamin D deﬁciency (25OHD3 <15 ng/ml) was more common in female recipients at
CKD-T stages I–III (29.6% vs 44.4%; p = 0.003). The inverse and signiﬁcant correlation between
25OHD3 and PTH was gender-speciﬁc and women exhibited a steeper slope than men
(p  = 0.01). Vertebral fractures (VFx) with deformity grade ≥2 were observed in 15% of recipi-
ents. Factors related to VFx differed by gender; in males, age (OR 1.04; 95% CI 1.01–1.06) and
CsA treatment (OR: 3.2; 95% CI: 1.6–6.3); in females, age (OR 1.07; 95% CI: 1.03–1.12) and PTH
levels (OR per 100 pg/ml increase: 1.27; 95% CI: 1.043–1.542). Abdominal aortic calciﬁcations
were common (67.2%) and related to classical risk factors but not to mineral metabolism
parameters.
Conclusions: Vitamin D deﬁciency is more common among female kidney transplant recipi-
ents  at earlier CKD-T stages, and it contributes to secondary hyperparathyroidism. Prevalent
vertebral fractures are only related to high serum PTH levels in female recipients.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Alteraciones  del  metabolismo  mineral,  fracturas  vertebrales,  y
calciﬁcaciones  aórticas  en  receptores  estables  de  trasplante  renal:  papel
del  género  (estudio  EMITRAL)
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Antecedentes y objetivos: La relación entre las alteraciones del metabolismo mineral, las frac-
turas óseas y las calciﬁcaciones vasculares en receptores de un trasplante renal no han sido
establecidas.
Método: Realizamos un estudio transversal en 727 receptores estables procedentes de 28
centros de trasplante espan˜oles. Se determinaron de manera centralizada los parámet-
ros  del metabolismo mineral; también se centralizó la semicuantiﬁcación de las fracturas
vertebrales y de las calciﬁcaciones de la aorta abdominal.
Resultados: La deﬁciencia de vitamina D (25OHD3 < 15 ng/ml) fue más  frecuente en mujeres y
en  los estadios CKD-T I-III (29,6 vs. 44,4%; p = 0,003). La relación inversa y signiﬁcativa obser-
vada entre los niveles de 25OHD3 y PTH fue modiﬁcada por el género de tal manera que
la  pendiente fue mayor en las mujeres que en los hombres (p = 0,01). Un 15% de los recep-
tores mostró alguna fractura vertebral (VFx) con un grado de deformidad ≥2. Los factores
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relacionados con la VFx diferían en función del género: en los hombres, la edad (OR: 1,04; IC
95%: 1,01-1,06) y el tratamiento con CsA (OR: 3,2; IC 95: 1,6-6,3); en las mujeres la edad (OR:
1,07;  IC 95%: 1,03-1,12) y los niveles de PTH (OR per 100 pg/ml increase: 1,27; IC 95%: 1,043-
1,542). Las calciﬁcaciones de la aorta abdominal fueron comunes (67,2%) y se relacionaron
con  los factores de riesgo clásicos, pero no con los parámetros del metabolismo mineral.
Conclusiones: La deﬁciencia de vitamina D es más frecuente en las mujeres receptoras de un
trasplante renal y en los estadios más tempranos de la CKD-T, y es un factor que contribuye
al  desarrollo de hiperparatiroidismo secundario. Las VFx prevalentes están relacionadas con
unos niveles más elevados de PTH solamente en las mujeres.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo  Open Access bajo la CC BY-NC-ND licencia (http://creativecommons.org/licencias/
by-nc-nd/4.0/).
Introduction
Mineral and bone disorders (MBD), inherent complications of
moderate and advanced chronic kidney disease, are frequent
in stable kidney transplant (KT) recipients.1,2 Prevalent PTH
levels are elevated at each CKD-T stage, and vitamin D insufﬁ-
ciency and deﬁciency are common.3–6 Mineral disorders have
been suggested to be associated with post-transplant out-
comes, such as higher serum phosphate, calcium7,8 and FGF23
levels,9 and are associated with increased mortality after KT.
Bone fractures are common after KT, and their cumula-
tive incidence is higher than in the general and haemodialysis
populations.10,11 The lower extremities are the most common
locations,10,11 but the prevalence of asymptomatic vertebral
deformities detected by vertebral morphometry has been
described in up to 30–50% of stable KT recipients.12,13 Age,
gender, and diabetes are common risk factors.10–13 However,
the role of mineral alterations, including PTH and 25OHD3 lev-
els, is unclear. Retrospective and cross-sectional studies have
shown that persistent hyperparathyroidism is a risk factor
for fracture after renal transplantation.13,14 However, whether
gender modiﬁes the relationship between mineral alterations
and bone fractures is still unknown.
The presence of preexisting vascular calciﬁcations of the
aorta and iliac arteries at the time of KT is an independent
predictor of both cardiovascular and all-cause mortality.15
Coronary and aortic calciﬁcation progression, assessed by spi-
ral CT, is substantial within 4 years in prevalent KT recipients
and is associated with several traditional and nontraditional
cardiovascular risk factors.16 Higher serum phosphate and
lower serum 25OHD3 levels are independent predictors of cal-
ciﬁcation progression.16
The relationship between MBD,  bone fractures, and vascu-
lar calciﬁcation in the setting of KT is undetermined. The aim
of this multicentre, cross-sectional study was to evaluate the
mineral metabolism parameters at different stages of CKD-T
and their relationship with prevalent vertebral fractures and
abdominal aorta calciﬁcation scores in a large sample of stable
KT recipients. Since female gender is a risk factor for bone frac-
tures after transplantation (10–13), we especiﬁcally examined
differences according to gender and whether gender modi-
ﬁes the relationship between mineral bone disorders and bone
fractures and vascular calciﬁcations.
Methods
Design,  setting,  and  participants
A cross-sectional study of 727 stable KT recipients from 28
transplant clinics across Spain (95.4% single kidney deceased
donor; 1.2% double kidney deceased donor, and 3.3% liv-
ing donor) was performed. At the time of the study, a
blood sample and lateral X-ray of the dorsal and lumbar
spines were obtained and sent to a central laboratory and
X-ray diagnosis unit, respectively. Demographic and clinical
data were retrospectively recorded from each participant’s
chart.
The vast majority of patients were Caucasian (95%).
Inclusion criteria were: age > 18 years, date of transplan-
tation between January 2008 to December 2010, and post-
transplantation time ≥1 year. The exclusion criteria were:
pregnancy, double transplant (except double kidney), cancer
(except non-melanoma skin cancer), signiﬁcant liver disease,
and the use of drugs possibly affecting bone and mineral
metabolism other than the usual post-transplant medica-
tions.
The number of patients included in each CKD-T stage
was estimated according to the 95% conﬁdence interval of
the variance observed for phosphate levels in the UK Renal
Registry.3 This required a total of 1106 patients to be included.
Because 28 out of 34 centres participated, we  were able
to enrol 766 patients (68.7%). For logistical reasons, central
laboratory determinations were unavailable for 39 patients.
Consequently, a total of 727 patients were enrolled (Fig. 1): 512
stage 1–3 T and 215 stage 4–5 T. This sample size gave a pre-
cision >95% to estimate the phosphate levels of CKD-T stages
I–III from the UK Registry. In order to avoid bias, the number
of patients included per transplant centre was proportional
to the number of kidney transplantations performed per year
at that centre, ranging from 5 to 33. In addition, each centre
included consecutive patients who fulﬁlled the inclusion crite-
ria and attended the outpatient clinic at some point between
April 2010 and February 2011.
No signiﬁcant differences were observed between the 39
recruited patients who did not have a central laboratory deter-
mination and the 727 patients who were ultimately included
in this study (data not shown).
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34 centers invited to participate
n=1106
28 participating centers
n=766
N=727 participants
(central lab mineral metabolism determinations)
N=39
(no central lab determinations)
N=615
Central lab mineral metabolism determinations
+ valid central vertebral deformity 
assessment
N=595
Central lab mineral metabolism determinations
+ valid central vertebral deformity assessment
+ valid central abdominal aorta calcification 
semiquantification
Fig. 1 – Study ﬂow chart.
Measurements
Demographic and clinical data were recorded from each
participant, including a history of clinical fractures and
parathyroidectomy. Past and current immunosuppression,
as well as bone and mineral medications (calcium and/or
vitamin D supplements, vitamin D receptor activators, phos-
phate binders, calcimimetics and bisphosphonates), were also
recorded. Graft function was derived from the MDRD-IV for-
mula as the eGFR. Proteinuria in a 24-hour sample or as the
protein/creatinine ratio (mg/g creatinine) in a ﬁrst morning
voided sample was also measured using standard methods at
each participating centre.
A blood sample was obtained from each participant, and
serum albumin, total calcium, phosphate, total and bone-
speciﬁc alkaline phosphatase, PTH, 25OHD3, and 1,25(OH)2D3
levels were evaluated at a central laboratory. Calcium
levels were corrected with serum albumin.17 PTH and
25OHD3 (Liaison®) were measured by chemiluminescence
(Immulite®); 1,25(OH)2D3 was measured by RIA (LKB Counter),
and bone alkaline phosphatase was measured by IRMA (LKB
Counter). Serum creatinine determination at each study Cen-
tre was calibrated to be traceable to IDMS. The seasons of the
year when the samples were obtained were: spring, 43.7%;
summer, 37.3%; autumn, 18%; and winter, 1%. New onset dia-
betes was deﬁned as a fasting glucose ≥126 mg/dl in the two
most recent determinations or the use of anti-diabetic drugs.
Ischaemic heart disease, cerebrovascular disease, peripheral
vascular disease were deﬁned by standard clinical criteria.18
At enrolment, lateral X-rays of the dorsal and lumbar spine
were obtained. Vertebral morphometry was assessed using the
semi-quantitative method of Genant.19 Brieﬂy, a decrease in
the anterior, mid-body, or posterior vertebral height of 20–25%
was considered mild (grade 1), 25–40% moderate (grade 2),
and >40% severe (grade 3) (Supplementary Figure 1). Similarly,
calciﬁcations of the abdominal aorta were assessed with the
semi-quantitative method of Kaupila20 and scored from 0 to a
maximum of 24. Both vertebral morphometry and abdominal
aorta calciﬁcation were centrally semi-quantiﬁed by an expert
radiologist or nephrologist, respectively, who lacked knowl-
edge of the patient’s clinical and biochemistry data. Valid data
for vertebral deformities were obtained in 615 cases and for
aortic calciﬁcation in 595 (Fig. 1). No signiﬁcant differences
were found in age, gender, time after transplantation, or min-
eral metabolism parameters between the recipients with or
without a valid assessment of vertebral deformities or aortic
calciﬁcation, with the exception of 25OHD3 levels which were
slightly higher in those with a valid assessment of vertebral
deformity (18.2 ± 9.9 and 21.8 ± 13.3 ng/ml; p = 0.04).
The Ethics Committee of the Hospital Universitario de
Canarias approved the study, and each participant signed an
informed consent form.
Statistics
Continuous variables are expressed as the mean and SD or
median and interquartile range, as appropriate. Absolute and
relative frequencies were used to describe the categorical
variables. Variables with a skewed distribution were log trans-
formed. Univariate analysis for two groups was performed
using the t test or Mann–Whitney U test, as appropriate. For
more  than two groups, we  used ANOVA or Kruskal–Wallis one-
way analysis of variance by ranks, as appropriate. Categorical
data were compared using the chi-square test. Correlations
between biochemical parameters were performed by uni-
variate regression analysis after log transformation of PTH,
25OHD3 and 1,25(OH)2D3 levels. We also performed partial
correlation analysis to investigate the relationship between
25OHD3 and PTH levels, as well as between 25OHD3 and
1,25(OH)2D3 levels, after adjusting for the eGFR.
A binary backward multivariable logistic regression anal-
ysis was performed to investigate the following: (a) variables
independently associated with grade ≥2 vertebral deformity
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and (b) variables independently associated with an abdom-
inal aorta calciﬁcation score in the third versus ﬁrst tertile.
Variables with p < 0.2 in the univariate analysis or known to be
clinically important were introduced in the multivariable anal-
ysis. We  did not violate the rule of a minimum of 10 events per
predictor variable to achieve the most parsimonious model.
The Hosmer–Lemeshow goodness of ﬁt was the principal crite-
rion for selecting the ﬁnal model. All analyses were performed
using SPSS 18 (Chicago, IL).
Results
Patient  characteristics
Table 1 shows the demographic, clinical, and biochemical data
as a function of the CKD-T stage at the time of the study.
Additionally, the percentage of patients with grade ≥2 verte-
bral deformity and an aortic calciﬁcation score >0 is shown.
Age, female gender, time since transplantation, a history of
acute rejection, patients on steroids, and proteinuria signiﬁ-
cantly increased with advancing CKD-T stage. The proportion
of patients receiving oral calcium (as supplement or as a
phosphate binder), as well as vitamin D receptor activators,
increased with advancing CKD-T stages. Serum PO4 and PTH
levels increased while serum calcitriol decreased with advanc-
ing CKD-T stages. Hypercalcemia (>10.3 mg/dl) was observed
in 6.5% of recipients and hypophosphatemia (<2.5 mg/dl) in
6.2%. PTH levels were above the normal (>70 pg/ml) in 76.9%
of patients. Vitamin D insufﬁciency (15–30 ng/ml) or deﬁciency
(<15 ng/ml) was observed in 50.8% and 32.5% of patients,
respectively. Therefore, only 16.7% of patients had normal
serum vitamin D levels.
The prevalence of compression fractures (grade ≥2) was
14.6%, which was not signiﬁcantly different across CKD-T
stages. Overall, 67.2% of patients had some degree of abdom-
inal aortic calciﬁcation; however, this proportion increased at
CKD-T stages III–V compared with stages I/II. Immunosup-
pression and the percentage of patients on statins (57%) or
ACEI/ARA (56%) were not different among CKD-T stages.
Gender  differences
Table 2 shows a comparison of male vs. female recipients. Esti-
mated GFR, 25OHD3 and 1,25(OH)2D3 levels were signiﬁcantly
lower in female recipients. Serum calcium and phosphate
levels were signiﬁcantly higher in female recipients, and
no signiﬁcant differences were observed in the circulating
levels of PTH or bone alkaline phosphatase. A signiﬁcantly
higher proportion of women were receiving oral calcium (as a
supplement or as a binder), vitamin D supplements, and bis-
phosphonates. Although a history of clinical fractures after
transplantation was more  common in female recipients (5.9
vs. 1.2%, respectively), prevalent vertebral fractures with verte-
bral deformity grade ≥2 at the time of study were less common
in women (10.9% vs. 17.1%).
To avoid the confounding effect of eGFR differences, a com-
parison of the mineral metabolism parameters by gender in
each CKD-T stage is provided in Supplementary Table 1. The
eGFR was similar in each CKD-T stage. As shown in Fig. 2a,
serum calcium was signiﬁcantly higher in women in CKD-T
I/II. As a result, more  women were receiving a calcimimetic
in this stage (16.7% vs. 4.3%; p = 0.03). Serum calcium and
phosphate levels were signiﬁcantly higher in CKD-T stage III
women (Fig. 2a and b), and a higher proportion of women were
treated with vitamin D derivatives (35.9% vs. 26%; p = 0.045)
and oral calcium supplements (24.6% vs. 16.5%; p = 0.06) com-
pared with men. Serum PTH and 1,25(OH)2D3 levels were
similar between men  and women at each CKD-T stage (Fig. 2c
and d).
Overall, 25OHD3 levels were not signiﬁcantly different
between genders at each CKD-T stage; however, the proportion
of women  with vitamin D deﬁciency (<15 ng/ml) was higher
than in men  in CKD-T stages I–III (36.8% vs. 26.9%; p = 0.02)
but not in CKD-T stages IV (36.6% vs. 35.2%) or V (50% vs.
60%). After excluding patients receiving vitamin D supplemen-
tation, gender differences in vitamin D deﬁciency at CKD-T
I–III increased (44.4% vs. 29.6%; p = 0.003) (Fig. 3a); in addition,
serum 25OHD3 levels were signiﬁcantly lower in women com-
pared with men  at CKD-T stages I–III (Supplementary Table 1;
Fig. 3b, p = 0.003), which was not the case for stages IV and
V. These differences in vitamin D status by gender were not
explained by the season of the year when the blood sam-
ples were collected (males: 52.8% in summer or autumn, 46%
in spring, and 1.1% in winter; females: 59% in summer or
autumn, 40.3% in spring, and 0.7% in winter).
The log transformed serum PTH levels correlated inversely
with the eGFR (r = −0.33; p < 0.001), albumin corrected serum
calcium (r = −0.14; p < 0.001) and log transformed 25OHD3 lev-
els (r = −0.23; p < 0.001). After adjusting for eGFR by partial
correlation analysis, the inverse correlation between PTH and
25OHD3 levels remained signiﬁcant (r = −0.22; p < 0.001). In
patients who were not treated with vitamin D supplements,
the slope of the regression line between 25OHD3 and PTH
levels was steeper in women than in men  (−0.25 ± 0.08 vs.
−0.62 ± 0.13; p = 0.01; Fig. 3c). The log transformed serum cal-
citriol levels correlated directly with eGFR (r = 0.44; p < 0.001)
and, as shown, the log transformed 25OHD3 levels (r = −0.35;
p < 0.001) (Fig. 3d). The correlation between 25OHD3 and cal-
citriol levels remained signiﬁcant after adjusting for eGFR
(r = −0.36; p < 0.001).
Factors  related  with  prevalent  vertebral  fractures
The prevalence of asymptomatic vertebral deformity grade ≥1
was 26%. Compression fractures that were grade 2 (deformity
>25%) or higher were found in 15% of the patients. Table 3
shows the univariate comparison of patients with and with-
out a prevalent asymptomatic vertebral fracture, deﬁned as a
deformity ≥grade 2. Patients with a prevalent vertebral frac-
ture were older, and vertebral fractures were more  common
in men  than in women. A postmenopausal status was more
prevalent among women with vertebral fractures. A history
of previous cardiovascular disease was more  common among
patients with vertebral fractures. Immunosuppression was
different between the groups, and CsA use was more common
among patients with vertebral fractures than those without
a vertebral fracture (22.2% vs. 10.9%, respectively; p = 0.006).
Indeed, 26% of patients treated with CsA and 13% of those
treated with tacrolimus or mTOR  inhibitors had a vertebral
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Table 1 – Demographic, clinical, and biochemical data of 727 kidney transplant recipients from 28 transplant clinics as a
function of their CKD-T stage. Mean and standard deviation or median and interquartile range as appropriate, are shown.
CKD-T stage
I/II (n = 136)
CKD-T stage III
(n = 376)
CKD-T stage
IV (n = 198)
CKD-T stage V
(n = 17)
p  Values
Age, yrs 51(13) 56(13) 57(13) 53 (11) I/II vs III**
I/II vs IV**
Sex, % females 31% 38% 47% 71% < 0.01
Time on dialysis, months 23 (11–40) 22 (11–39) 23 (12–39) 27 (14–68) I/II vs V*
Time since transplantation (Tx), months 61 (40–84) 66 (41–97) 74 (49–101) 67 (41–92) I/II vs IV**
III vs IV*
History of cardiovascular disease 15% 22% 19% 19% 0.3
BMI, kg/m2 26(4) 27(4) 27(5) 24(2) 0.1
Pretransplant DM/NODAT, % 6%/19% 9%/15% 13%/17% 6%/15% 0.1/0.7
Parathyroidectomy PreTx/PostTx, % 4%/1% 6%/1% 5%/1% 19%/0% 0.08/0.9
Patients on steroids, % 61% 71% 81% 100% < 0.01
Current prednisone dose, mg/day 2.5 (0–5) 5 (0–5) 2.5 (3–5) 5 (5–5) I/II vs III**
I/II vs IV**
I/II vs V**
III vs IV**
III vs V**
IV vs V*
Patients on tacrolimus/CsA/mTORi, % 77/10/14 70/14/16 69/15/15 79/12/18 0.3/0.5/0.9
Patients on MMF, % 86% 86% 81% 59% < 0.05
Acute rejection, % 9% 20% 26% 44% < 0.01
Proteinuria ≥300 mg/day 12% 24% 46% 56% < 0.01
Patients on oral calcium, % 13% 20% 26% 65% < 0.01
Patients on vitamin D supplements, % 13% 19% 25% 24% = 0.08
Patients on calcitriol/paricalcitol, % 8%/1% 11%/1% 24%/7% 18%/24% 0.01/0.01
Patients on calcimimetic, % 8% 8% 10% 18% 0.5
Patients on bisphosphonates, % 6% 6% 7% 6% 0.9
Corrected total Ca, mg/dl 9.5(0.5) 9.5(0.5) 9.4(0.7) 9.3(0.8) 0.1
Phosphate, mg/dl 3.2(0.6) 3.3(0.6) 3.8(0.8) 5(0.9) I/II vs IV**
I/II vs V**
Total AP, U/L 81(31) 82(32) 81(38) 80(33) 0.9
Bone AP, pg/ml 12 (9–16) 12 (9–16) 12 (9–18) 13 (9–19) 0.4
PTH, pg/ml 82 (60–118) 110 (71–176) 185 (108–293) 385 (198–559) I/II vs III**
I/II vs IV**
I/II vs V**
III vs IV**
III vs V**
IV vs V**
25OHD3, ng/ml 19 (14–27) 20 (13–27) 18 (13–25) 12 (11–23) I/II vs V*
III vs V*
1,25(OH)2D3, pg/ml 51 (38–62) 38 (29–52) 28 (20–38) 18 (12–26) I/II vs III**
I/II vs IV**
I/II vs V**
III vs IV**
III vs V**
IV vs V**
History of clinical fractures before/after
transplantation, %
2%/2% 2%/3% 3%/4% 6%/6% 0.7/0.8
Prevalent vertebral deformity ≥grade 2, %
(n = 618)
13%  16% 13% 14% 0.2
Abdominal aortic calciﬁcation score >0, %
(n = 595)
56%  68% 72% 80% < 0.05
Pulse pressure, mm Hg 52(13) 58(16) 62(18) 64(15) I/II vs III*
I/II vs IV**
I/II vs V*
III vs IV*
CKD-T stages I >90; II 60–89; III 30–59; IV 15–29; V <15 ml/mn/1.73 m2. NODAT, new onset diabetes after transplantation; AP, alkaline phosphatase.
∗ p < 0.05.
∗∗ p < 0.01.
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Table 2 – Demographic, clinical, and biochemical data of 721 kidney transplant recipients from 28 transplant clinics as a
function of gender. Mean and standard deviation or median and interquartile range as appropriate, are shown.
Males
(n = 437)
Females
(n  = 290)
p  Value
Age, yrs 55(14) 55(13) 0.8
Time on dialysis, months 23 (12–40) 20 (11–37) 0.1
Time since transplantation (Tx), months 65 (42–95) 70 (45–96) 0.4
History of cardiovascular disease, % 22 16 0.04
BMI, kg/m2 31(30) 31(35) 0.8
Pretransplant DM or NODAT, % 26 24 0.6
Parathyroidectomy PreTx/PostTx, % 4/1 7/1 0.04/1
Patients on steroids, % 73 71 0.5
Current prednisone dose, mg/day 5 (0–5) 5 (0–5) 0.3
Patients on tacrolimus/CsA/mTORi, % 72/15/16 73/12/16 0.8/0.4/0.9
Patients on MMF, % 84 84 1
Acute rejection, % 20 20 0.9
eGFR, mlmn/1.73 m2 45 (20) 40 (2) 0.001
Proteinuria ≥300 mg/day 37% 24% 0.01
Patients on oral calcium, % 19  25 0.05
Patients on Vitamin D supplements, % 17  24 0.04
Patients on calcitriol/paricalcitol, % 13/3  15/4 0.7/0.5
Patients on calcimimetic, % 8 10 0.3
Patients on bisphosphonates, % 4 10 0.002
Corrected total Ca, mg/dl 9.4(0.5) 9.6(0.6) 0.001
Phosphate, mg/dl 3.4(0.7) 3.7(0.8) 0.001
Total AP, U/L 82(33) 90(34) 0.6
Bone AP, pg/ml 12 (9–16) 12 (9–16) 0.8
PTH, pg/ml 111
(71–193)
180  (179) 0.2
25OHD3, ng/ml
All, n = 359
No Vit D Suppl, n = 221
20  (14–27)
19 (13–26)
18  (12–25)
16 (11–22)
0.04
0.001
1,25(OH)2D3, pg/ml 38 (27–53) 35 (26–49) 0.02
History of clinical fractures before/after
transplantation, %
2/2  2/5 0.8/0.02
Vertebral deformity ≥grade 2, % 17 (63/368) 11 (27/247) 0.04
Abdominal aortic calciﬁcation score >0, % 67%
(237/353)
67%
(162/242)
1
Pulse pressure, mm Hg 58(15)  59(18) 0.6
NODAT, new onset diabetes after transplantation; AP, alkaline phosphatase.
fracture (p = 0.005). Using backward conditional logistic
regression analysis, we investigated the factors indepen-
dently related to prevalent vertebral fractures. We included
age, gender, BMI, time since transplantation, corticosteroid
treatment (dichotomic), CsA treatment (dichotomic), eGFR,
serum 25OHD3, and PTH levels as independent variables.
Age, gender, and treatment with CsA were independently
associated with prevalent vertebral fractures (Table 4). We also
explored the interactions between gender and different min-
eral metabolism variables. The only signiﬁcant interaction
was gender*PTH (p = 0.016). Therefore, it was logical to proceed
with separate analyses of men  (n = 368) and women (n = 235).
Men  with vertebral fractures were older (60 ± 12 vs. 54 ± 14
years; p = 0.001) and more  commonly received CsA as the
maintenance immunosuppressant (27% vs. 12.5%; p = 0.006)
than those without fractures. No other signiﬁcant difference
was observed between the two groups (data not shown). Using
backward conditional logistic regression analysis, we  investi-
gated the factors independently related to prevalent vertebral
fractures in men. We  included age, BMI, time since transplan-
tation, corticosteroid treatment, CsA treatment, eGFR, serum
25OHD3, and PTH levels as independent variables. Age and
CsA treatment, but not time since transplantation, were inde-
pendent factors associated with vertebral fractures (Table 4).
Additionally, time since transplantation was not statistically
signiﬁcant when excluding immunosuppression therapy from
the model (p = 0.7).
Women with vertebral fractures were older (63.4 ± 9 vs.
54.2 ± 13 years; p < 0.001) and had higher serum PTH [216
(92–412) vs. 114 (71.8–189.8) pg/ml, p = 0.007] and lower 25OHD3
levels [14.8 (10.4–20.9) vs. 18.4 (12.3–26.3) ng/ml; p = 0.049) than
women without fractures (no other signiﬁcant difference was
observed between the groups; data not shown). By backward
logistic regression analysis, age and serum PTH levels were
signiﬁcantly related to vertebral fractures after adjusting for
the eGFR and 25OHD3 level. Interestingly, and unlike male
recipients, immunosuppression was not related to vertebral
fractures in women.
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Fig. 2 – Albumin-corrected total serum calcium (a), serum phosphate (b), PTH (c), and 1,25(OH)2D3 (d) by CKD-T stages as a
function of gender. Female vs male gender: (*) p < 0.001; (**) p = 0.02. Mean ± SE.
Compared to patients receiving tacrolimus or mTORi at
the time of the study, those who  were treated with CsA had
a longer post-transplantation time. This difference was sim-
ilar in men  (85 ± 26.6 vs. 66.1 ± 30.5 months; p < 0.001) and
women (93.9 ± 26.3 vs. 67.7 ± 30.7 months; p < 0.001). However,
the prevalence rates of vertebral fractures in patients who
were treated with CsA differed by gender, 31.5% vs. 14.6%
(p = 0.005) in men  and 10.7% vs. 13% (p = 0.8) in women.
Factors  related  to  aortic  calciﬁcation
A Kaupila’s score ≥1 was observed in 67.2% of the patients.
Table 5 shows the univariate comparison of patients as a
function of their tertile of calciﬁcation score. Age, time since
transplantation, pulse pressure, and proportion of patients
with prior ischaemic heart disease increased with the sever-
ity of abdominal aorta calciﬁcation (Table 5). Conversely, eGFR
decreased with increasing calciﬁcation. Mineral metabolism
parameters were not signiﬁcantly different among the calciﬁ-
cation tertiles.
Using backward logistic regression analysis, age [OR 1.03
(1.02–1.05)], time since transplantation [OR 1.01 (1.001–1.02)],
and history of ischaemic heart disease [2.4 (1.07–5.7)] were
independent predictors of the highest calciﬁcation score (third
tertile) compared with patients who lacked calciﬁcation (ﬁrst
tertile). No mineral metabolism parameters were related to
aortic calciﬁcation.
Discussion
This cross-sectional study included a large sample of stable
KT recipients (>1 year after transplantation) with different
CKD-T stages, which are representative of current clinical
practice across Spain. We observed that secondary hyper-
parathyroidism was common among stable KT recipients,
and a low 25OHD3 level was a contributing factor. Vitamin
D deﬁciency was more  common in female participants at
earlier CKD-T stages; in addition, the relationship between
25OHD3 and PTH levels was modiﬁed by gender. Prevalent
vertebral fractures were more  common in males and related
to age and CsA treatment as well as to age and PTH level
in females. Abdominal aortic calciﬁcation was common and
mainly related to time since transplantation and traditional
risk factors.
Serum phosphate and PTH levels increased and calcitriol
levels decreased with increasing CKD-T stage (Table 1), as
reported in non-transplanted CKD patients.21,22 The preva-
lence of vitamin D deﬁciency or insufﬁciency was high in
our study (83%), in agreement with other studies.4,5,23,24 An
increased conversion of calcidiol to calcitriol, owing to high
PTH levels, could be a contributing factor because 1,25(OH)2D3
levels correlated directly with 25OHD3 levels (Fig. 2D). We
also report a higher prevalence of vitamin D deﬁciency
(25OHD3 < 15 ng/ml) among female recipients, which was only
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Fig. 3 – Prevalence of Vitamin D deﬁciency (25OHD3 <15 ng/ml) by the CKT-T stage as a function of gender (a). For those
recipients who  were  not treated with vitamin D, 25OHD3 by CKD-T stage serum levels (b) and correlation of log transformed
25OHD3 with log transformed PTH levels are shown as a function of gender (slope was steeper in women; p = 0.01). For all
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p < 0.001) (d). (*) p = 0.003 for the comparison of males vs females in CKD-T Stages I through III; for CKD-T stages IV–V no
signiﬁcant differences between males vs. females.
observed at earlier stages of CKD-T (eGFR >30 ml/mn). Inter-
estingly, vitamin D deﬁciency has also been reported more
frequently in women within the ﬁrst 30 days after KT.25 There
may not be gender differences in the rate of conversion of
25OHD3 to 1,25(OH)2D3 because the slopes of the regres-
sion lines were similar in males and females. Additionally,
most blood collections at enrolment were performed during
the spring or summer, and the natural seasonal changes in
25OHD3 levels did not affect our results. Therefore, further
research is required to explain the gender differences in the
prevalence of vitamin D deﬁciency among KT recipients.
An inverse correlation between 25OHD3 and PTH levels
was found in this and other studies.4,5,23,24 Thus, the KDIGO
guidelines for KT recipients suggest that vitamin D deﬁciency
and insufﬁciency should be corrected in patients with CKD
stages 1–5 T using treatment strategies that are recommended
for the general population.25 Our data suggest this is espe-
cially relevant among female recipients because vitamin D
deﬁciency is not only more  common in women, but in addi-
tion, for a given decrease in 25OHD3 level the corresponding
increase in the PTH level is also higher than in male recipients
(Fig. 2C). Treatment with nutritional vitamin D signiﬁcantly
increases the 25OHD3 level and decreases the PTH level in KT
recipients.26-28
Asymptomatic vertebral compression fractures (VFx) of
any grade were observed in 26% of our patients. This rate
is lower than the 32–57% prevalence reported in other
studies that recruited fewer recipients.12,13 However, minor
deformities of the midthoracic spine (especially in women)
and thoracolumbar junction (especially in men) have been
described in normal individuals.19 Thus, we only considered
grade 2 or 3 vertebral compression as VFx. Remarkably, the 15%
prevalence found in our study is higher than the 10% preva-
lence observed in Spanish postmenopausal women older than
50 years of age,29 which still contrasts with the less than 2%
found in transplant recipients when searching according to
the medical records (Table 3).30 Regardless of the deﬁnition,
the importance of detecting prevalent VFx lies in the fact that
they are risk factors for subsequent fractures.19,31 As expected,
asymptomatic VFx increased with age, but surprisingly, they
were more  common in men  than women (Table 3). However,
a higher proportion of female recipients had a previous clini-
cal fracture and, consequently, were more  commonly treated
with bisphosphonates at the time of the study (9.7 vs. 3.9%;
p = 0.002). Although asymptomatic vertebral fractures in the
elderly may be more  frequent in men  than in women,31 the
role of gender in the epidemiology of fractures after kidney
transplantation may be different in the central versus periph-
eral location.
Compared with tacrolimus or mTORi, the use of CsA was a
risk factor for VFx in males, but not in females, independently
of post-transplantation time, history of acute rejection, or
current corticosteroid use (Tables 3 and 4). Although the effect
of CsA on bone metabolism in humans is controversial,32 it
induces high turnover osteopenia in rats, more  pronounced
with CsA than with tacrolimus.33 Interestingly, the effect of
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Table 3 – Univariate comparison of the patients with and without a prevalent vertebral fracture, deﬁned as a ≥2 grade
deformity. Mean and standard deviation or median and interquartile range as appropriate, are shown.
No vertebral
fracture
(n = 525)
Vertebral
fracture
(n  = 90)
p  Value
Age, yrs 54(13)  61(11) 0.001
Sex, % females
% Postmenopausal
42
65
30
85
0.04
0.05
Time on dialysis, months 22 (11–40) 25 (13–38) 0.2
Time since transplantation (Tx), months 70(42–96) 63 (45–95) 0.6
History of cardiovascular disease, % 19 29% 0.1
BMI, kg/m2 27(4) 27(4) 0.6
Pretransplant DM/NODAT, % 9/16 13/20 0.3/0.3
Pretransplant/post-transplant parathyroidectomy, % 5/1 7/0 0.6/1
History of clinical fractures, pretransplant/post-transplant, %
History of clinical vertebral fracture, %
2/3
0
3/2
1
0.1/1.
0.3
Patients on steroids, % 72 71 0.9
Current prednisone dose, mg/day 5
(0–5)
5
(0–5)
0.5
Patients on Tacrolimus/CsA/mTORi, % 74/11/10 65/22/14 0.05/0.01/0.8
Patients on MMF, % 83  88 0.4
History of acute rejection, % 20 24 0.4
eGFR, ml/mn/1.73 m2 43(19) 43(19) 0.9
Proteinuria ≥300 mg/day 35% 32% 0.4
Patients on oral calcium therapy, % 23 20 0.6
Patients on nutritional vitamin D therapy, % 20 17 0.5
Patients on calcitriol/paricalcitol therapy, % 13/3 17/2 0.3/0.8
Patients on calcimimetic therapy, % 8 10 0.5
Bisphosphonates therapy, % 7 7 1
Corrected total Ca, mg/dl 9.5(0.6) 9.4(0.6) 0.6
Phosphate, mg/dl 3.5(0.8) 3.4(0.8) 0.4
Total AP, U/L 81(33) 85(32) 0.2
Bone AP, pg/ml 12 (9–17) 13 (10–16) 0.6
PTH, pg/ml 114 (72–197) 134
(73–218)
0.2
25OHD3, ng/ml 19 (14–27) 17 (13–26) 0.3
1,25, OH2D3, pg/ml 37 (26–52) 40 (29–53) 0.4
Patients on statins, % 57 64 0.2
Abdominal aortic calciﬁcation score >0, %, n = 595 66 69 0.6
Pulse pressure, mm Hg 58(16) 62(18) 0.02
NODAT, new onset diabetes after transplantation; AP, alkaline phosphatase.
Table 4 – Multivariate logistic regression analysis.
Dependent variable: prevalent vertebral fracture (grade
≥2 deformity).
All (n = 603)*
Independent variable OR (95% CI) p
Age 1.04 (1.02–1.06) 0.0001
Sex 1.70 (1.01–2.80) 0.04
Immunosuppression with CsA 2.50 (1.40–4.60) 0.003
Males (n = 368)*
Age 1.04 (1.01–1.10) 0.004
Immunosuppression with CsA 3.20 (1.60–6.30) 0.001
Females (n = 235)**
Age 1.07 (1.03–1.10) 0.01
Serum PTH (100 pg/ml increase) 1.27 (1.04–1.54) 0.017
* Adjusted by time after transplantation, BMI, eGFR, corticosteroid
use, and serum levels of 25OHD3 and PTH. ** Adjusted by eGFR.
CsA on bone resorption has been described in male but not
female rats.34 However, given the retrospective and cross-
sectional nature of the present study, the speciﬁc negative
effect of CsA on VFx in males has to be interpreted with
caution and merits further investigation and validation in
other studies.
In a previous cross-sectional study of 102 KT recipients,
high PTH levels were associated with an increased risk of
VFx.13 In the present study, including 368 men  and 247 women
with a valid vertebral morphometry, there was a gender-
related association, and women, but not men, with VFx
exhibited higher PTH levels. This suggests that high PTH lev-
els in females may explain the increased and unbalanced bone
turnover after renal transplantation, leading to bone loss and
fractures. Indeed, a differential bone protective effect of the
bisphosphonate risedronate was recently observed in female
but not male kidney transplant recipients.35 Future studies are
needed to determine whether the use of paricalcitol or cinacal-
cet to control persistent post-transplant hyperparathyroidism,
as previously reported,36–38 impacts the fracture incidence of
female recipients.
Older age, prior ischaemic heart disease, and a longer
time since transplantation, but not gender, were risk factors
for abdominal aortic calciﬁcation. Interestingly, these factors
were predictors of the progression of coronary and thoracic
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Table 5 – Comparison of abdominal aortic calciﬁcation by the tertiles of Kaupila’s score. Mean and standard deviation or
median and interquartile range as appropriate are shown.
Tertile 1 (score = 0)
(n = 195)
Tertile 2 (score 1–6)
(n = 195)
Tertile 3 (score >6)
(n = 205)
p  Value
Age, yrs 52(14)  56(12) 57(12) <0.01 (T1 vs T2
and T3)
Sex, % females
% Postmenopausal
41
51
41
64
41
83
1
0.001
Time on dialysis, months 20 (12–36) 23 (12–39) 23 (11–45) 0.4
Time since transplantation (Tx), months 65 (40–89) 63 (38–96) 75 (49–100) 0.02
History of cardiovascular disease, % 18 21 25 0.3
History of ischaemic heart disease, % 7 9 15 0.03
Patients on statins, % 55 58 57 0.8
Patients on ACE/ARA, % 56 60 54 0.4
BMI, Kg/m2 26(5) 27(4) 27(4) 0.8
Pretransplant DM/NODAT, % 10/14 11/17 9/17 0.8/0.7
Pretransplant/post-transplant parathyroidectomy, % 6/0 5/1 6/2 1/0
Patients on steroids, % 72 71 74 0.8
Current prednisone dose, mg/day 5 (0–5) 5 (0–5) 5 (0–5) 0.4
Patients on tacrolimus/CsA/mTORi, % 74/12/15 73/14/18 69/14/18 0.5/0.9/0.6
Patients on MMF, % 87  85 80 0.2
eGFR, ml/mn/1.73 m2 45.3(21) 41(18) 40.6(18) 0.05 T1 vs T3
Proteinuria ≥300 mg/day 33% 36% 33% 0.8
Patients on oral calcium therapy, % 26 20 23 0.4
Patients on nutritional vitamin D therapy, % 11 13 15 1
Patients on calcitriol/paricalcitol therapy, % 11/3 11/3 18/4 0.06/0.7
Patients on calcimimetic therapy, % 7 7 11 0.3
Bisphosphonates therapy, % 7 6 7 0.9
Corrected total Ca, mg/dl 9.4(0.6) 9.5(0.6) 9.5(0.6) 0.3
Phosphate, mg/dl 3.5(0.5) 3.5(0.8) 3.5(0.7) 1
Total AP, U/L 80(30) 85(40) 80(29) 0.2
Bone AP, pg/ml 12 (9–16) 13 (9–18) 12 (9–16) 0.4
PTH, pg/ml 108 (72–189) 133 (78–207) 115 (70–228) 0.3
25OHD3, ng/ml 20 (15–28) 19 (13–27) 20 (14–25) 0.4
1,25, OH2D3, pg/ml 38 (29–51) 36 (25–53) 36 (26–51) 0.2
History of clinical fractures,
pretransplant/post-transplant, %
3/4  2/3 3/2 0.6/0.6
Vertebral deformity grade ≥2, % 13 18 13 0.4
Pulse pressure, mm Hg 57(16) 58(17) 60(17) 0.09
ACE/ARA, angiotensin converting enzyme inhibitors/angiotensin receptor antagonists; NODAT, new onset diabetes after transplantation; AP,
alkaline phosphatase.
aorta calciﬁcation in a recent cohort study of prevalent KT
recipients.16 In that study, low 25OHD3 and high serum phos-
phate levels at baseline were related to progression of coronary
and thoracic aorta calciﬁcation, respectively.16 The fact that
alterations of mineral metabolism were not related to abdom-
inal aorta calciﬁcation in our study suggests that calciﬁcation
at this location is mainly related to the common risk fac-
tors for atherosclerosis. In fact, a recent study performed in
non-dialysis CKD patients (OSERCE-2 study) showed that the
Adragao score, which includes the evaluation of hand arteries,
but not the Kauppila score, was related to phosphorus levels.39
Our study has limitations. First, this was a cross-sectional
study; therefore, a cause–effect relationship cannot be
inferred. Tobacco exposure and lipid levels were not estimated
as risk factors for abdominal aortic calciﬁcation; however,
a history of smoking was not a determinant of vascular
calciﬁcation progression in a recent cohort study.16 With
these limitations, our study reﬂects the variability of differ-
ent clinical practices across 28 transplant centres, making the
observed associations more  robust for planning preventive
interventions.
In conclusion, vitamin D deﬁciency is more  common
among female KT recipients at earlier CKD-T stages and is
a contributing factor to secondary hyperparathyroidism. In
addition, gender modiﬁes the relationship between 25OHD3
and PTH levels, and women have a steeper slope. Finally,
prevalent vertebral fractures are not more  common in females,
but they are only related to high serum PTH levels in female
recipients.
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